|
|
Article: Nanobac Pharmaceuticals Acquires Option to License Calgenex Technology to Treat Atherosclerosis and Prostatitis.
- Article from:
- Business Wire
- Article date:
- October 3, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla. -- Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announced today that it signed an agreement with Calgenex granting Nanobac an option to assess Calgenex' drug delivery technology for potential use with Nanobac's drug combinations used in treating atherosclerosis, prostatitis, and other pathologic calcification diseases. The technology includes a novel combination of bisphosphonate and silicic acid.
"Today's option agreement is a testament towards our goal of evaluating the best therapeutic delivery technologies used with our compounds to treat diseases associated with pathologic calcification," commented Alex H. Edwards III ...